6 completed, 2 active not recruiting, 2 withdrawn, 1 recruiting. 11 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 6, Active not recruiting 2, Withdrawn 2, Recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow IPI-145: new trials by email Literature Review of IPI-145 trials Research Report on IPI-145
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Follicular Helper T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | City of Hope Medical Center | 25 | 2026-08-03 | 2026-10-19 |
| Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Duvelisib - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 15 | 2020-05-13 | 2026-01-05 |
| A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma Duvelisib - Indolent Non-Hodgkin Lymphoma | Phase 2 | Completed | SecuraBio | 103 | 2019-09-24 | 2024-09-19 |
| Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS Duvelisib, Venetoclax - Chronic Lymphocytic Leukemia, Richter Syndrome | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 55 | 2018-07-12 | 2026-10-28 |
| A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Duvelisib - Peripheral T-cell Lymphoma | Phase 2 | Completed | SecuraBio | 156 | 2018-02-22 | 2025-03-07 |
| A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145) Duvelisib - Hematologic Malignancy | Phase 2 | Completed | SecuraBio | 19 | 2016-04-01 | 2023-09-11 |
| Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) Duvelisib, Rituximab, R-CHOP - Lymphoma | Phase 2 | Withdrawn | SecuraBio | 2015-12-01 | 2021-03-17 | |
| A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL IPI-145, Fludarabine, Cyclophosphamide - Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 32 | 2014-06-27 | 2026-10-22 |
| IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) IPI-145, Follow-up Visit/Call - Leukemia | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2013-12-01 | 2014-01-06 | |
| A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma Duvelisib - Indolent Non-Hodgkin Lymphoma | Phase 2 | Completed | SecuraBio | 129 | 2013-06-17 | 2023-09-07 |
| A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone IPI-145, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | SecuraBio | 322 | 2013-04-01 | 2021-03-17 |
Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma (2) · Lymphoma, T-Cell (2) · Arthritis, Rheumatoid (1) · Burkitt Lymphoma (1) · Hematologic Neoplasms (1) · Leukemia (1) · Lymphoma, T-Cell, Peripheral (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
SecuraBio (6) · City of Hope Medical Center (2) · Dana-Farber Cancer Institute (2) · M.D. Anderson Cancer Center (1)
United States (9) · Italy (4) · Germany (3) · United Kingdom (3) · Bulgaria (2) · Czechia (2) · Hungary (2) · Poland (2) · Russia (2) · Belarus (1) · Belgium (1) · Canada (1) · Colombia (1) · France (1) · Georgia (1)
Hagop Youssoufian, MD (2) · Alexey V Danilov (1) · Christina Poh (1) · Matthew Davids, MD (1) · Matthew S Davids, MD (1) · Susan O'Brien, MD, BA (1)
PMID 30742566, PMID 38836342, PMID 41886642, PMID 42018969
2019 (2), P30CA033572 (2), 2015 (1)